Explore

Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026

Nuvectis Pharma Reports Increased Net Loss in Q1 2026

Nuvectis Pharma Reports Increased Net Loss in Q1 2026
Trendline Trendline
Vertex Pharmaceuticals Reports Strong Q1 2026 Financial Results with 8% Revenue Growth

Vertex Pharmaceuticals Reports Strong Q1 2026 Financial Results with 8% Revenue Growth

Vertex Pharmaceuticals Reports Strong Q1 2026 Financial Results with 8% Revenue Growth
Trendline Trendline
IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Expansion Plans

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Expansion Plans

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Expansion Plans
Trendline Trendline
Sarepta, Amylyx, and Neumora Anticipate Key Developments Amidst Q1 Earnings

Sarepta, Amylyx, and Neumora Anticipate Key Developments Amidst Q1 Earnings

Sarepta, Amylyx, and Neumora Anticipate Key Developments Amidst Q1 Earnings
Trendline Trendline
Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results

Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results

Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results
Trendline Trendline
NImmune Biopharma Presents Promising Data for IBD Treatment at Digestive Disease Week

NImmune Biopharma Presents Promising Data for IBD Treatment at Digestive Disease Week

NImmune Biopharma Presents Promising Data for IBD Treatment at Digestive Disease Week
Trendline Trendline
Arrowhead Pharmaceuticals Licenses RNAi Therapeutic for MASH to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals Licenses RNAi Therapeutic for MASH to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals Licenses RNAi Therapeutic for MASH to Madrigal Pharmaceuticals
Trendline Trendline
Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept
Trendline Trendline
ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates
Trendline Trendline
Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark

Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark

Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark